Neuroprotective effects of zonisamide target astrocyte

Masato Asanuma, Ikuko Miyazaki, Francisco J. Diaz-Corrales, Naotaka Kimoto, Yuri Kikkawa, Mika Takeshima, Ko Miyoshi, Miho Murata

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Objective: Recent double-blind, controlled trials in Japan showed that the antiepileptic agent zonisamide (ZNS) improves the cardinal symptoms of Parkinson's disease. Glutathione (GSH) exerts antioxidative activity through quenching reactive oxygen species and dopamine quinone. GSH depletion within dopaminergic neurons impairs mitochondrial complex I activity, followed by age-dependent nigrostriatal neurodegeneration. This study examined changes in GSH and GSH synthesis-related molecules, and the neuroprotective effects of ZNS on dopaminergic neurodegeneration using 6-hydroxydopamine-injected hemiparkinsonian mice brain and cultured neurons or astrocytes. Methods and Results: ZNS increased both the cell number and GSH levels in astroglial C6 cells, but not in dopaminergic neuronal CATH.a cells. Repeated injections of ZNS (30mg/kg intraperitoneally) for 14 days also significantly increased GSH levels and S100β-positive astrocytes in mouse basal ganglia. Repeated ZNS injections (30mg/kg) for 7 days in the hemiparkinsonian mice increased the expression of cystine/glutamate exchange transporter xCT in activated astrocytes, which supply cysteine to neurons for GSH synthesis. Treatment of these mice with ZNS also increased GSH levels and completely suppressed striatal levodopa-induced quinone formation. Reduction of nigrostriatal dopamine neurons in the lesioned side of hemiparkinsonian mice was significantly abrogated by repeated injections of ZNS with or without adjunctive levodopa starting 3 weeks after 6-hydroxydopamine lesioning. Interpretation: These results provide new pharmacological evidence for the effects of ZNS. ZNS markedly increased GSH levels by enhancing the astroglial cystine transport system and/or astroglial proliferation via S100β production or secretion. ZNS acts as a neuroprotectant against oxidative stress and progressive dopaminergic neurodegeneration.

Original languageEnglish
Pages (from-to)239-249
Number of pages11
JournalAnnals of Neurology
Volume67
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

zonisamide
Neuroprotective Agents
Astrocytes
Cystine
Oxidopamine
Dopaminergic Neurons
Levodopa
Injections
Amino Acid Transport System X-AG
Neurons
Corpus Striatum

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Asanuma, M., Miyazaki, I., Diaz-Corrales, F. J., Kimoto, N., Kikkawa, Y., Takeshima, M., ... Murata, M. (2010). Neuroprotective effects of zonisamide target astrocyte. Annals of Neurology, 67(2), 239-249. https://doi.org/10.1002/ana.21885

Neuroprotective effects of zonisamide target astrocyte. / Asanuma, Masato; Miyazaki, Ikuko; Diaz-Corrales, Francisco J.; Kimoto, Naotaka; Kikkawa, Yuri; Takeshima, Mika; Miyoshi, Ko; Murata, Miho.

In: Annals of Neurology, Vol. 67, No. 2, 02.2010, p. 239-249.

Research output: Contribution to journalArticle

Asanuma, M, Miyazaki, I, Diaz-Corrales, FJ, Kimoto, N, Kikkawa, Y, Takeshima, M, Miyoshi, K & Murata, M 2010, 'Neuroprotective effects of zonisamide target astrocyte', Annals of Neurology, vol. 67, no. 2, pp. 239-249. https://doi.org/10.1002/ana.21885
Asanuma M, Miyazaki I, Diaz-Corrales FJ, Kimoto N, Kikkawa Y, Takeshima M et al. Neuroprotective effects of zonisamide target astrocyte. Annals of Neurology. 2010 Feb;67(2):239-249. https://doi.org/10.1002/ana.21885
Asanuma, Masato ; Miyazaki, Ikuko ; Diaz-Corrales, Francisco J. ; Kimoto, Naotaka ; Kikkawa, Yuri ; Takeshima, Mika ; Miyoshi, Ko ; Murata, Miho. / Neuroprotective effects of zonisamide target astrocyte. In: Annals of Neurology. 2010 ; Vol. 67, No. 2. pp. 239-249.
@article{bf6fb45e57ca4cafa8763349c6660007,
title = "Neuroprotective effects of zonisamide target astrocyte",
abstract = "Objective: Recent double-blind, controlled trials in Japan showed that the antiepileptic agent zonisamide (ZNS) improves the cardinal symptoms of Parkinson's disease. Glutathione (GSH) exerts antioxidative activity through quenching reactive oxygen species and dopamine quinone. GSH depletion within dopaminergic neurons impairs mitochondrial complex I activity, followed by age-dependent nigrostriatal neurodegeneration. This study examined changes in GSH and GSH synthesis-related molecules, and the neuroprotective effects of ZNS on dopaminergic neurodegeneration using 6-hydroxydopamine-injected hemiparkinsonian mice brain and cultured neurons or astrocytes. Methods and Results: ZNS increased both the cell number and GSH levels in astroglial C6 cells, but not in dopaminergic neuronal CATH.a cells. Repeated injections of ZNS (30mg/kg intraperitoneally) for 14 days also significantly increased GSH levels and S100β-positive astrocytes in mouse basal ganglia. Repeated ZNS injections (30mg/kg) for 7 days in the hemiparkinsonian mice increased the expression of cystine/glutamate exchange transporter xCT in activated astrocytes, which supply cysteine to neurons for GSH synthesis. Treatment of these mice with ZNS also increased GSH levels and completely suppressed striatal levodopa-induced quinone formation. Reduction of nigrostriatal dopamine neurons in the lesioned side of hemiparkinsonian mice was significantly abrogated by repeated injections of ZNS with or without adjunctive levodopa starting 3 weeks after 6-hydroxydopamine lesioning. Interpretation: These results provide new pharmacological evidence for the effects of ZNS. ZNS markedly increased GSH levels by enhancing the astroglial cystine transport system and/or astroglial proliferation via S100β production or secretion. ZNS acts as a neuroprotectant against oxidative stress and progressive dopaminergic neurodegeneration.",
author = "Masato Asanuma and Ikuko Miyazaki and Diaz-Corrales, {Francisco J.} and Naotaka Kimoto and Yuri Kikkawa and Mika Takeshima and Ko Miyoshi and Miho Murata",
year = "2010",
month = "2",
doi = "10.1002/ana.21885",
language = "English",
volume = "67",
pages = "239--249",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Neuroprotective effects of zonisamide target astrocyte

AU - Asanuma, Masato

AU - Miyazaki, Ikuko

AU - Diaz-Corrales, Francisco J.

AU - Kimoto, Naotaka

AU - Kikkawa, Yuri

AU - Takeshima, Mika

AU - Miyoshi, Ko

AU - Murata, Miho

PY - 2010/2

Y1 - 2010/2

N2 - Objective: Recent double-blind, controlled trials in Japan showed that the antiepileptic agent zonisamide (ZNS) improves the cardinal symptoms of Parkinson's disease. Glutathione (GSH) exerts antioxidative activity through quenching reactive oxygen species and dopamine quinone. GSH depletion within dopaminergic neurons impairs mitochondrial complex I activity, followed by age-dependent nigrostriatal neurodegeneration. This study examined changes in GSH and GSH synthesis-related molecules, and the neuroprotective effects of ZNS on dopaminergic neurodegeneration using 6-hydroxydopamine-injected hemiparkinsonian mice brain and cultured neurons or astrocytes. Methods and Results: ZNS increased both the cell number and GSH levels in astroglial C6 cells, but not in dopaminergic neuronal CATH.a cells. Repeated injections of ZNS (30mg/kg intraperitoneally) for 14 days also significantly increased GSH levels and S100β-positive astrocytes in mouse basal ganglia. Repeated ZNS injections (30mg/kg) for 7 days in the hemiparkinsonian mice increased the expression of cystine/glutamate exchange transporter xCT in activated astrocytes, which supply cysteine to neurons for GSH synthesis. Treatment of these mice with ZNS also increased GSH levels and completely suppressed striatal levodopa-induced quinone formation. Reduction of nigrostriatal dopamine neurons in the lesioned side of hemiparkinsonian mice was significantly abrogated by repeated injections of ZNS with or without adjunctive levodopa starting 3 weeks after 6-hydroxydopamine lesioning. Interpretation: These results provide new pharmacological evidence for the effects of ZNS. ZNS markedly increased GSH levels by enhancing the astroglial cystine transport system and/or astroglial proliferation via S100β production or secretion. ZNS acts as a neuroprotectant against oxidative stress and progressive dopaminergic neurodegeneration.

AB - Objective: Recent double-blind, controlled trials in Japan showed that the antiepileptic agent zonisamide (ZNS) improves the cardinal symptoms of Parkinson's disease. Glutathione (GSH) exerts antioxidative activity through quenching reactive oxygen species and dopamine quinone. GSH depletion within dopaminergic neurons impairs mitochondrial complex I activity, followed by age-dependent nigrostriatal neurodegeneration. This study examined changes in GSH and GSH synthesis-related molecules, and the neuroprotective effects of ZNS on dopaminergic neurodegeneration using 6-hydroxydopamine-injected hemiparkinsonian mice brain and cultured neurons or astrocytes. Methods and Results: ZNS increased both the cell number and GSH levels in astroglial C6 cells, but not in dopaminergic neuronal CATH.a cells. Repeated injections of ZNS (30mg/kg intraperitoneally) for 14 days also significantly increased GSH levels and S100β-positive astrocytes in mouse basal ganglia. Repeated ZNS injections (30mg/kg) for 7 days in the hemiparkinsonian mice increased the expression of cystine/glutamate exchange transporter xCT in activated astrocytes, which supply cysteine to neurons for GSH synthesis. Treatment of these mice with ZNS also increased GSH levels and completely suppressed striatal levodopa-induced quinone formation. Reduction of nigrostriatal dopamine neurons in the lesioned side of hemiparkinsonian mice was significantly abrogated by repeated injections of ZNS with or without adjunctive levodopa starting 3 weeks after 6-hydroxydopamine lesioning. Interpretation: These results provide new pharmacological evidence for the effects of ZNS. ZNS markedly increased GSH levels by enhancing the astroglial cystine transport system and/or astroglial proliferation via S100β production or secretion. ZNS acts as a neuroprotectant against oxidative stress and progressive dopaminergic neurodegeneration.

UR - http://www.scopus.com/inward/record.url?scp=77949380692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949380692&partnerID=8YFLogxK

U2 - 10.1002/ana.21885

DO - 10.1002/ana.21885

M3 - Article

C2 - 20225289

AN - SCOPUS:77949380692

VL - 67

SP - 239

EP - 249

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 2

ER -